Relay Therapeutics (Nasdaq: RLAY), a clinical-stage small molecule precision medicine company focused on therapies for cancer and genetic diseases, plans to report its second quarter 2026 financial results and corporate highlights after U.S. market close on Thursday, August 6, 2026.
The announcement outlines the timing of the upcoming financial disclosure and related corporate update, allowing investors and analysts to prepare for Relay Therapeutics’ next scheduled earnings communication.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
Relay’s prior earnings-date announcements produced 3.1% and -1.81% 24-hour reactions, providing mixe...
Analysis
Relay’s prior earnings-date announcements produced 3.1% and -1.81% 24-hour reactions, providing mixed historical context for this scheduling notice. Current insider context was Net Selling; the August 6 report remains the key watchpoint.
Scheduled fourth-quarter and full-year results for February 26
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Earnings-date announcements had mixed reactions, with one positive and one negative 24-hour move.
Key Terms
small molecule, precision medicine
2 terms
small moleculetechnical
"clinical-stage, small molecule precision medicine company"
A small molecule is a low-weight chemical compound that can enter cells easily and interact with specific proteins or biological pathways to change how they work, much like a small key fitting into a lock. Investors care because small molecules are a common and often faster route to develop medicines, can be manufactured at scale, and may offer clearer regulatory and commercial paths compared with larger biologic therapies, affecting potential costs, timelines and returns.
precision medicinemedical
"small molecule precision medicine company developing potentially life-changing therapies"
Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report second quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 6, 2026.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.
When will Relay Therapeutics (Nasdaq: RLAY) report Q2 2026 financial results?
Relay Therapeutics will report its Q2 2026 financial results on Thursday, August 6, 2026. According to Relay Therapeutics, the release will occur after U.S. financial markets close, alongside an update on the company’s corporate highlights for the quarter.
What will Relay Therapeutics (RLAY) announce on August 6, 2026?
Relay Therapeutics will announce its second quarter 2026 financial results and corporate highlights on August 6, 2026. According to Relay Therapeutics, the update will be released after U.S. markets close and will cover financial performance and recent business developments.
At what time will Relay Therapeutics release Q2 2026 results on August 6, 2026?
Relay Therapeutics plans to release Q2 2026 results after U.S. financial markets close on August 6, 2026. According to Relay Therapeutics, investors can expect both financial results and corporate highlights following the end of the regular U.S. trading session that day.
What type of company is Relay Therapeutics (RLAY) reporting Q2 2026 earnings?
Relay Therapeutics is a clinical-stage small molecule precision medicine company. According to Relay Therapeutics, it is developing potentially life-changing therapies for patients with cancer and genetic disease and will report Q2 2026 financial results and corporate highlights on August 6, 2026.
Why is the August 6, 2026 date important for Relay Therapeutics (RLAY) investors?
August 6, 2026 is the scheduled date for Relay Therapeutics’ Q2 2026 financial results and corporate highlights. According to Relay Therapeutics, the post-close release will provide updated financial information and business developments relevant to shareholders and potential investors.
